SunTrust analyst David MacDonald lowered his price target on UnitedHealth to $300 to reflect the compression in market multiples but also keeps his Buy rating on the company after the company's Q1 results that were "marked by solid core trends across both divisions and a well managed medical cost trend." The analyst notes that the industry concerns around Medicare for America and Affordable Care Act programs are weighing on the stock, but he sees "structural changes to the model as quite low" and remains "bullish" on the shares. MacDonald adds that UnitedHealth's free cash flows remain "robust", capital deployment opportunities are "plentiful" and its "valuation risk/reward is compelling."

Deutsche Bank analyst George Hill raised the firm's price target on UnitedHealth to $562 from $545 and keeps a Buy rating on the shares. The company reported a Q1 earnings beat with many moving pieces caused by the cyberattack on Change Healthcare, which left earnings quality and guidance up to investor interpretation, the analyst tells investors in a research note. The firm sees the full impact of the hack, as well as conservatism around cost trend and utilization would impact UnitedHealth earnings by only 2% for the full year.

Notable gainers among liquid option names this morning include Genuine Parts (GPC) $159.09 +15.03, Globe Life (GL) $66.97 +3.74, Anthem (ELV) $532.10 +23.13, United Continental (UAL) $50.59 +1.84, and UnitedHealth (UNH) $494.80 +15.81.

Unusual total active option classes on open include: Wrap Technologies (WRAP), AstraZeneca (AZN), JetBlue (JBLU), United Continental (UAL), Taiwan Semi (TSM), Nokia (NOK), EBay (EBAY), Maplebear Inc (CART), Airbnb (ABNB), and UnitedHealth (UNH).

RBC Capital analyst Ben Hendrix lowered the firm's price target on UnitedHealth to $555 from $596 but keeps an Outperform rating on the shares. The company reported a "better than feared" Q1, but the debate over utilization trends is expected to persist through the first half as excess reserves skew the medical care ratio picture, the analyst tells investors in a research note. RBC also notes that its added caution reflects UnitedHealth's "reduced claims visibility".